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Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic,
neurologic disease in young adults. While approximate values of the disease burden of
MS are known, individual drivers are unknown.
Objective: To estimate the age-, sex-, and disease severity-specific contributions to the
disease burden of MS.
Methods: We estimated the disease burden of MS using disability-adjusted life years
(DALYs) following the Global Burden of Disease study (GBD) methodology. The data
sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the
Swiss mortality registry.
Results: The disease burden of MS in Switzerland in 2016 was 6,938 DALYs
(95%-interval: 6,018-7,955), which corresponds to 97 DALYs per 100,000 adult
inhabitants. Morbidity contributed 59% of the disease burden. While persons in an
asymptomatic (EDSS-proxy 0) and mild (EDSS-proxy >0–3.5) disease stage represent
68.4% of the population, they make up 39.8% of the MS-specific morbidity. The
remaining 60.2% of the MS-specific morbidity stems from the 31.6% of persons in a
moderate (EDSS-proxy 4–6.5) or severe (EDSS-proxy ≥7) disease stage.
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Conclusions: Morbidity has a larger influence on the disease burden of MS than
mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild
and moderate/severe disease stage in Switzerland. Interventions to reduce severity
worsening in combination with tailored, symptomatic treatments are important future
paths to lower the disease burden of MS.
Keywords: burden, DALY, morbidity, mortality, SMSR, epidemiology
INTRODUCTION
The disease burden is one of the most important indicators for
the relevance of a certain condition, both from a societal as well as
an individual perspective. The most commonly employed metric
to describe the disease burden are Disability-Adjusted Life Years
(DALYs). DALYs consist of two components. On the one hand,
Years Lived with Disability (YLD) measure the burden in terms
of the health-related quality of life (HRQoL) reduction of persons
currently living with a disease. On the other hand, Years of Life
Lost (YLL) quantify the effects of premature deaths accountable
to the disease in terms of life-span reduction. Summing up these
two components yields DALYS (1–3).
The Global Burden of Disease (GBD) 2016 Multiple Sclerosis
Collaborators (2019) estimated that there are 2.2 million persons
with Multiple Sclerosis (MS) worldwide and that 0.04% of all
DALYs are due to MS. While these numbers might not seem
extraordinarily high at first glance, they are nevertheless highly
relevant because of the frequent onset of MS early in life (between
30 and 40 years) and the lack of a curative treatment. In fact,
MS is the most common chronic, inflammatory, neurologic
disease in young adults and therefore constitutes a comparatively
high disease burden in younger age groups, with substantial
reductions of health-related quality of life and significant health
care need (4). Moreover, the prevalence in Western Europe and
many other regions is relatively high and possibly rising. With an
estimated prevalence of 174–187 cases per 100,000 inhabitants,
Switzerland also represents a high prevalence country, but some
estimates for other countries range even higher, exceeding 220
cases per 100,000 and with an increasing incidence (5, 6).
The disease burden of MS has been estimated previously
for Switzerland in the context of larger, international consortia,
which emphasized cross-country comparisons rather than more
detailed estimates. Therefore, the results were either presented
as summary measures pooling all disease stages or emphasized
utility estimations (4, 7). More detailed, sub-group specific
burden estimates are lacking. This knowledge gap is regrettable
from a public health perspective as more detailed assessments
reflecting the different disease-severity and age structure of the
population of persons with MS (PwMS) are of high relevance
to health policy and care providers. For example, measures of
disease burden facilitate the evidence-based allocation of limited
health care resources.
Our aim was two-fold: (i) to estimate the overall disease
burden of MS in Switzerland and (ii) to identify the relative
contributions of age-, sex-, and disease severity-specific
subgroups to the overall disease burden of MS.
METHODS
Study Population
For the present estimation, we used distributions of sex, age
and disease severity obtained from the Swiss Multiple Sclerosis
Registry (SMSR) on the basis of 1,412 PwMS (as of April 4, 2019;
Table 1). The SMSR is an ongoing, prospective, observational,
patient-centred study of adult PwMS in Switzerland. The
information is directly obtained from PwMS through online
participation or questionnaires on paper and is supplemented
by a physician’s confirmation of the diagnosis as well as
further clinical information for a selected subpopulation. The
structure of the SMSR was specifically developed to also include
participants who are commonly not included in clinical studies
as, for example, persons who were diagnosed recently, are highly
disabled or treated by physician that do not actively participate
in research (8, 9). In this manner, we were able to include the
full spectrum of PwMS in Switzerland and minimize under-
representations in the tails of the age-distribution. The SMSR
study was approved by the ethics committee of the canton
of Zurich (PB-2016-00894, BASEC 2019-01027) and written
informed consent was obtained from all SMSR participants (8).
All data were pseudonymised prior to analysis.
TABLE 1 | Demographics and disease characteristics of the Swiss MS Registry
sample.
Swiss MS registry
Sample size 1,412
Sex female (%) 1,030 (72.9%)
Median age (IQR) 48.0 (38.0-56.0)
Current MS type
RRMS (%) 1,007 (71.3%)
SPMS (%) 252 (17.8%)
PPMS (%) 153 (10.8%)
Disease severity
Asymptomatic 145 (10.3%)
Mild 821 (58.1%)
Moderate 333 (23.6%)
Severe 113 (8.0%)
Median utility (IQR) 0.776 (0.637–0.916)
Median disease duration since diagnosis (IQR) 8.5 (3.1–16.5)
Median disease duration since first symptoms (IQR) 12.4 (5.2–21.0)
Median age at diagnosis (IQR) 36 (28–45)
IQR, interquartile range; RRMS, relapsing-remitting MS; SPMS, secondary-progressive
MS; PPMS, primary-progressive MS.
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The prevalence numbers needed for themorbidity component
of the DALYs are based on the prevalence estimation of the study
of Kaufmann et al. (5). Regarding the mortality component of
the DALYs estimation, two different data sources were combined.
The number of deaths, stratified by sex and age, were obtained in
an aggregated form from the Swiss mortality registry (10). This
registry includes persons for whom MS was recorded as main
or secondary cause of death. Data on age- and sex-specific life
expectancy in Switzerland were obtained from the Swiss federal
statistical office (11, 12).
Estimation of Disability-Adjusted Life Years
(DALYs)
We followed the methodology that has previously been used by
the GBD study called H-DALYs by Schroeder (1–3, 13). The
DALYs were estimated by summing up YLD and YLL (DALYs
= YLD + YLL) and no age weighting or discounting was
considered. YLD were defined as
YLD =
∑
i, j, k
(Pijk∗DWk) (1)
and YLL as
YLL =
∑
i, j
(Dij∗Lij) (2)
with i and j being the indices for the age and sex groups and k the
index for the disease severity groups. P stands for the prevalence,
DW the disability weight, D the number of deaths and L the age-
and sex-specific life expectancy.
Specifically, we worked with 17 age groups (18–19, 20–24,...,
90–94, and 95 and older), two sex groups (female and male) and
four disease severity groups [asymptomatic (EDSS-proxy 0), mild
(EDSS-proxy >0–3.5), moderate (EDSS-proxy 4–6.5), severe
(EDSS-proxy 7–9.5)]. The EDSS-proxy values were estimated
based on an algorithm by Barin et al. which uses self-reported
mobility data (14). Furthermore, we added an asymptomatic
category based on no mobility impairment and no problems
in any of the five domains of the EQ-5D. The group-specific
prevalences were obtained by using sex, age and disease severity
distributions of the SMSR and by extrapolating the numbers
from the 2016 prevalence estimation of Kaufmann et al. (5, 8, 9).
The disability weights were used according to the GBD 2016
Multiple Sclerosis Collaborators (2019) (asymptomatic: 0 [0–0];
mild: 0.183 [0.124–0.253]; moderate: 0.463 [0.313–0.613]; severe:
0.719 [0.534–0.858]) (4). The number of deaths and the age-
and sex-specific life expectancy were obtained from the Swiss
mortality registry and the Swiss life expectancy table of 2016 by
the Swiss Federal Office of Statistics (10–12).
Statistical Analysis
We estimated YLD for every combination of sex, age and
disease severity and YLL for every combination of sex and
age according to Equations (1) and (2), respectively. Due to
the uncertainty in the estimation of the involved parameters
[prevalence (P), disability weight (DW) and number of deaths
(D)], theses parameters were not considered in a fixed manner.
Instead, each of them was presented as a range of plausible
values. For the estimation, these ranges were treated as
uniform distributions and one value sampled per parameter.
To reasonably represent the existing uncertainty in the results,
this estimation was repeated 1,000 times yielding a results
distribution. For prevalence, the plausibility range was defined
by the 95%-confidence interval previously reported in the
estimation of Kaufmann et al. (5). The plausibility range of the
disability weights was directly taken from the GBD 2016Multiple
Sclerosis Collaborators (2019) (4). The minimum and maximum
of the number of deaths was given by the number of deaths if MS
was considered as main cause of death only (lower limit), as well
as main or secondary cause (upper limit) (10).
From these numbers, DALYs as well sub-group specific
contributions to the disease burden of MS could be estimated.
Due to sometimes skewed distributions, all burden measures
are reported as medians (thus implying that subgroup specific
burden estimates may not add up perfectly to the overall
burden estimate).
As a sensitivity analysis, we re-estimated the disability weights
of the four disease severity categories using empirical EQ-5D
assessments from the SMSR using the French index value set and
subtracting the utilities from 1 (4, 14–17).
All statistical analyses were performed using R, version
3.6.0 (18).
RESULTS
Population characteristics were obtained from 1,412 PwMS
participating in the SMSR with a median age of 48 and a
percentage of women of 72.9% (Table 1). Relapsing-remitting
MS (RRMS) was the dominant disease course (71.3%), followed
by secondary-progressive MS (SPMS) (17.8%) and primary-
progressiveMS (PPMS) (10.8%). Themedian age at diagnosis was
36 years, and time since diagnosis (median 8.5 years) and since
first symptoms (median 12.4 years) were in the expected range.
Our estimation of the DALYs distribution of MS in
Switzerland in 2016 yielded a median disease burden of 6,938
DALYs (95% interval: 6,018–7,955 DALYs). Setting this estimate
into the context of the entire adult population of Switzerland
in 2016 (7,127,446), we arrived at a median disease burden of
MS of 97 DALYs per 100,000 adult inhabitants (95%-interval:
84–112 DALYs/100,000 inhabitants) (Figure A1). Looking at
the sex-specific numbers, women—representing almost three
quarters of individuals in the SMSR—contributed 67% of overall
DALYS while men contributed 33% (Figures A2, A3). All data
are displayed in Table 2.
The individual contributions of YLD and YLL were 59 and
41%, respectively. Per 100,000, this yields a median YLD of
58/100,000 (95%-interval: 46–72/100,000) and a median YLL of
39/100,000 (36–43/100,000). Furthermore, we examined at the
age- and sex-specific YLD and YLL patterns, shown in Figure 1.
In both sexes, YLD are dominant before, YLL after the age of 70.
The distribution in the SMSR shows that 68.4% of the
population are in an asymptomatic or mild disease stage
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(asymptomatic: 10.3%; mild: 58.1%) whereas 31.6% have a
moderate to severe disability (moderate: 23.6%; severe: 8.0%)
(Table 1). However, when examining the morbidity aspect of
DALYs (= YLDs), PwMS in an asymptomatic or mild disease
stage represent 39.8% of the MS-specific population morbidity
(asymptomatic: 0 [0%]; mild: 1,644 [39.8%]). PwMS with a
moderate to severe disability contribute 60.2% to the MS-specific
morbidity (moderate: 1,646 [39.9%]; severe 840 [20.3%]).
Regarding the sensitivity analysis and estimating disability
weights from the SMSR data, the results were all in a similar
range compared to the relatively wide ones of the GBD
2016 Multiple Sclerosis Collaborators (group-wise disability
weights: asymptomatic: SMSR interquartile range [IQR] 0–0,
TABLE 2 | Disease burden of multiple sclerosis in Switzerland in 2016.
DALYs YLD YLL
Absolute 6,938
(6,018–7,955)
4,129
(3,258–5,097)
2,811
(2,568–3,030)
Per 100,000 97 (84–112) 58 (46–72) 39 (36–43)
Women absolute 4,673
(4,039–5,404)
2,821
(2,208–3,486)
1,857
(1,656–2,036)
Women per 100,000 129 (112–149) 78 (61–96) 51 (46–56)
Men absolute 2,263
(1,953–2,588)
1,306
(1,043–1,603)
950 (813–1,090)
Men per 100,000 65 (56–74) 37 (30–46) 27 (23–31)
The first column displays Disability-Adjusted Life Years (DALYs) and columns 2 and 3
the two components of it, years lived with disability (YLD) and years of life lost (YLL),
respectively. The rows are always first displaying the absolute values and then the relative
ones per 100,000 inhabitants. Global Burden of Disease study estimates are displayed in
Table A1 (Supplementary Material).
GBD 95%-confidence interval [95% CI] 0–0; mild: SMSR IQR
0.105–0.271, GBD 95% CI 0.124–0.253; moderate: SMSR IQR
0.276–0.452, GBD 95% CI 0.313–0.613; severe: SMSR IQR 0.478–
0.730, GBD 95% CI 0.534–0.858) (4).
DISCUSSION
This study estimated the disease burden of multiple sclerosis
in Switzerland in the year 2016 and investigated age- and sex-
specific patterns. The median estimate was 97 DALYs per 100,000
inhabitants, with morbidity (YLD) being responsible for a share
of 59% (58/100,000). Although representing 72.9% of the whole
MS population, women contributed 2/3 of the overall disease
burden of MS. The data showed that YLD were the driver before,
YLL after the age of 70. While having a high population share
of 68.4%, PwMS with an asymptomatic or mild disease severity
make up about 39.8% of the morbidity-related, MS-specific
disease burden.
Setting the number of DALYs of our study into context,
they agree well with the estimate of the GBD study in 2016
for Switzerland (SMSR: 6,938 DALYs; GBD: 6,658 DALYs)
(Table 2 and Table A1) (4). However, at closer inspection, some
differences appear. The YLD components of our estimation is
larger (SMSR: 4,129; GBD: 3,588) which can be explained by
the fact that the prevalence estimation of the SMSR (considering
multiple Swiss databases and a refined methodology) is higher
(SMSR: ∼15,200; GBD: ∼13,950) and the GBD estimate is
corrected for co-morbidities. In turn, the YLL component of
the GBD estimate is larger (SMSR: 2,811; GBD: 3,070). This
is surprising because the number of deaths considered in the
GBD study (127) is at the lower end of our interval of possible
FIGURE 1 | Years lived with disability (YLD) and years of life lost (YLL) per 100,000 inhabitants stratified by age and sex. Panel (A) displays the distribution of YLD and
YLL components over the entire age spectrum for women, (B) for men. The two curves (YLL and YLD) are additive and summed up yield Disability-Adjusted Life Years
(DALYs).
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number of deaths (120–183). A possible explanation for the
differing assessments of YLL components might be that the
GBD studies, which are based on multinational data, potentially
assume that more deaths due to MS are occurring at younger
ages, which would directly scale with the extended age-specific
life expectancy (4).
MS plays a more important role regarding disease burden
in Switzerland compared to other regions of the world. The
burden ofMS contributes 0.4% to the total DALYs in Switzerland,
which is substantially more than the 0.04% worldwide, but
comparable to Northern European countries (19). This can
mainly be attributed to two causes. One is clearly the lower overall
disease burden in Switzerland (CH: 24,063 DALYs/100,000
inhabitants; world: 32,711/100,000). Second, MS has a higher
relative prevalence in Switzerland compared to other world
regions, where the overall burden is subject to stronger influences
of infectious diseases (4, 19).
MS is a substantial, though not one of the strongest drivers
of disease burden in Switzerland. For example, rheumatoid
arthritis makes up 0.32% of the total DALYs in Switzerland
per year, diabetes mellitus (type I and II) 3.56%, or Alzheimer’s
disease/dementias 3.79% (19). However, MS bears important
societal impacts, which are not represented by DALYs, for
example reduced work capacity or higher health-care costs,
due to its usually early onset between 30 and 40 and chronic
nature (7).
A striking finding that, to our knowledge, has not been
reported before is the distribution of the MS-specific morbidity
in the severity subgroups compared to their population share.
PwMS at an asymptomatic or mild disease stage make up 68.4%
of the Swiss MS population (10.3, 58.1%, respectively), however,
their share of the morbidity component—to which only the
mild disease stage contributes—is estimated to be 39.8%. If sex-
and age-specific utilities of persons in a mild disease stage are
compared to the general population, small but consistently lower
health utilities are present on average (between−0.02 and−0.08)
(17). Therefore, it seems that this group’s contribution to the
overall disease burden is mainly driven by its size. Moreover,
against the background of a comparatively small health utility
difference between the general population and persons with mild
MS, potential interventions such as novel disease modifying
treatments are likely to resound more on a population than an
individual level according to our analysis.
However, it also needs to be emphasized that population-level
burden and utilities do not necessarily reflect the individual, real-
world situation. The EDSS-based disease stage categorization
inherits the limitations of being mainly gait-focused and
somewhat subjective in certain areas (e.g., sensory function,
bowel, and bladder function). As a consequence, symptoms
like fatigue, cognitive disturbances, and depression are not
well-reflected in this categorization, although they are frequent
and highly influential on quality of life on an individual level
(14). This shortcoming can be seen in the wide ranges of the
disability weights within EDSS-based disease severity subgroups,
particularly in the sensitivity analysis based on utility data
from the SMSR. Future studies should also consider alternative
disease stage definitions, for example based on self-reported
health-related quality of life (e.g., measured by EQ-5D), to
achieve more reliable group-specific disease burden estimates.
Nonetheless, this recategorization is unlikely to affect the
overall disease burden—compared to the disease severity specific
burden—on a population level.
Independent of the above-mentioned short-comings, the
subgroup-specific burden estimates are highly relevant for
health-care policy stakeholders, since they may help to allocate
financial resources by refining macro-allocation strategies. In
particular, investments to reduce disease progression have the
potential to positively affect the disease burden. For example,
the expected demographic aging will likely lead to shifts toward
higher disability in the MS population as the age average
will increase. Treatments prolonging the transition to higher
disability, which coincides with rising age and MS duration,
could therefore act as an important lever to lower the overall
disease burden of MS. At the same time, assessing opportunities
to reduce or stabilize the morbidity in the entire spectrum,
for example, improved symptomatic pharmacological and non-
pharmacological treatment options or adjusted work possibilities,
would not only reduce or keep the disease burden of MS stable
but might also substantially influence the economic burden on a
population level. Whether these findings are context-specific to
Switzerland or valid for other European countries will have to
be determined.
Our study has notable strengths since the estimations are
based on several reliable and complementary data sources and a
thorough methodology. However, also several limitations exist.
Previous analyses of the Swiss MS Registry revealed a slight
under-representation of older age groups and higher disability,
with the potential to underestimate the burden. Nonetheless, we
are confident that the impact of this underrepresentation of older
age groups is small. In fact, a hypothetically missing group of
100 persons with a severe MS (disability weight: 0.719) would
only increase the overall DALYs by 71.9. Furthermore, in the
SMSR, only adult PwMS are considered, while the number of
pediatric cases in Switzerland is unknown. Assuming a similar
prevalence as reported by Marrie et al. (20), Switzerland would
have about 100 cases of pediatric MS. Together with the generally
higher utility, their impact on the population burden is likely
to be small as well. Next, the use of an EDSS-proxy instead of
a clinically assessed EDSS is expected to only marginally affect
the estimates because categorizations and not exact EDSS values
are used and a previous study showed a good accuracy of the
EDSS-proxy (14). Another source of uncertainty concerns the
mortality within the context of MS since the details of mortality
recording vary substantially in different mortality registries.
However, by including the range of MS being the main or a
secondary cause of death, the uncertainty of our estimate should
have been limited. All named limitations have been reduced
by the resampling approach applied in this study by reflecting
the uncertainty in the input parameters. As a final note, we
would like to highlight that we estimated the MS-specific disease
burden, which does not consider co-morbidities. Therefore, the
disease burden in persons with MS—compared to the disease
burden of MS—is likely still higher for two reasons. First, the co-
morbidities alone can increase the burden. Second, interactions
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of the diseases might amplify the burden of specific symptoms.
These patterns are more likely to be visible in older PwMS due
to their higher rate of co-morbidities. However, the extent to
which the population burden would be increased is unclear. A
study of our group showed a limited direct influence of co-
morbidities on the individual-level disease burden. Additionally,
our sensitivity analysis, based on the quality of life of PwMS
and therefore inherently also including co-morbidities, resulted
in similar disability weights as the GBD study.
We conclude that the disease burden of MS in Switzerland is
partitioned into 41% by mortality and 59% by morbidity. The
latter is shared in a ratio of 2:3 by the high proportion of persons
with asymptomatic or mild disease (68.4%) and the smaller
(31.6%), but more impaired group of persons with moderate
or severe disease disability. The further development of novel
disease-modifying therapies aimed to attenuate progression
in more advanced disease stages, might further increase the
morbidity-associated burden share, but could at the same time
also decrease the overall population level burden.
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